Long-Term Safety Study of Open-Label Pramipexole Extended Release (ER) in Patients With Early Parkinson's Disease (PD).
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Pramipexole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim
- 31 Aug 2018 Biomarkers information updated
- 15 Jun 2010 Actual number of patients added to 511 as reported by ClinicalTrials.gov.
- 14 Jun 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.